Hence, the synergetic therapeutic strategy to simultaneously inhibit the PD‐L1/PD‐1 pathway and IDO pathway could be an ideal choice for effectively relieving the immunosuppressive TME, leading to an enhanced cancer immunotherapy. This evidence concerns the gene IDO1 and cancer.